Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1984 Apr;17(4):453–458. doi: 10.1111/j.1365-2125.1984.tb02371.x

Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration.

M Eichelbaum, G Mikus, B Vogelgesang
PMCID: PMC1463390  PMID: 6721991

Abstract

The pharmacokinetics of (+)-, (-)-, and (+/-)-verapamil were studied in five healthy volunteers following i.v. administration of the drugs. Pronounced differences of the various pharmacokinetic parameters were observed between the (-)- and (+)-isomers. The values for CL, V, Vz, and Vss of the (-)-isomer were substantially higher as compared to the (+)-isomer, whereas terminal t 1/ 2Z was nearly identical for both isomers. No dose dependency of the pharmacokinetics could be observed in two subjects who received 5, 7.5 and 10 mg of (-)- and 5, 25 and 50 mg of (+)-verapamil. Protein binding for the two isomers was also different. The fu of (-)- (0.11) was almost twice as much as that of (+)-verapamil (0.064). Pharmacokinetic parameters of (+/-)-verapamil, which was administered to three subjects who had received (+)- and (-)-verapamil, were very similar to the averaged values of the isomers given separately. Due to the higher CL of (-)-verapamil the extraction ratio of the (-)-isomer is substantially higher. Thus, it can be anticipated that following oral administration of racemic verapamil bioavailability of (-)-verapamil will be substantially less. Since the (-)-isomer is more potent than the (+)-isomer, the present findings could explain the reported differences in the concentration-effect relationship after i.v. and oral administration of racemic verapamil.

Full text

PDF
455

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson P., BondessoN U., Sylvén C. Clinical pharmacokinetics of verapamil in patients with atrial fibrillation. Eur J Clin Pharmacol. 1982;23(1):49–57. doi: 10.1007/BF01061377. [DOI] [PubMed] [Google Scholar]
  2. Eichelbaum M., Albrecht M., Kliems G., Schäfer K., Somogyi A. Influence of meso-caval shunt surgery on verapamil kinetics, bioavailability and response. Br J Clin Pharmacol. 1980 Nov;10(5):527–530. doi: 10.1111/j.1365-2125.1980.tb01800.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Eichelbaum M., Birkel P., Grube E., Gütgemann U., Somogyi A. Effects of verapamil on P-R-intervals in relation to verapamil plasma levels following single I.V. and oral administration and during chronic treatment. Klin Wochenschr. 1980 Sep 15;58(18):919–925. doi: 10.1007/BF01477049. [DOI] [PubMed] [Google Scholar]
  4. Eichelbaum M., Dengler H. J., Somogyi A., von Unruh G. E. Superiority of stable isotope techniques in the assessment of the bioavailability of drugs undergoing extensive first pass elimination. Studies of the relative bioavailability of verapamil tablets. Eur J Clin Pharmacol. 1981 Jan;19(2):127–131. doi: 10.1007/BF00568399. [DOI] [PubMed] [Google Scholar]
  5. Eichelbaum M., Somogyi A., von Unruh G. E., Dengler H. J. Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotope-labelled verapamil. Eur J Clin Pharmacol. 1981 Jan;19(2):133–137. doi: 10.1007/BF00568400. [DOI] [PubMed] [Google Scholar]
  6. Freedman S. B., Richmond D. R., Ashley J. J., Kelly D. T. Verapamil kinetics in normal subjects and patients with coronary artery spasm. Clin Pharmacol Ther. 1981 Nov;30(5):644–652. doi: 10.1038/clpt.1981.216. [DOI] [PubMed] [Google Scholar]
  7. Johnston A., Burgess C. D., Hamer J. Systemic availability of oral verapamil and effect on PR interval in man. Br J Clin Pharmacol. 1981 Sep;12(3):397–400. doi: 10.1111/j.1365-2125.1981.tb01233.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kates R. E., Keefe D. L., Schwartz J., Harapat S., Kirsten E. B., Harrison D. C. Verapamil disposition kinetics in chronic atrial fibrillation. Clin Pharmacol Ther. 1981 Jul;30(1):44–51. doi: 10.1038/clpt.1981.125. [DOI] [PubMed] [Google Scholar]
  9. McAllister R. G., Jr, Kirsten E. B. The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses. Clin Pharmacol Ther. 1982 Apr;31(4):418–426. doi: 10.1038/clpt.1982.54. [DOI] [PubMed] [Google Scholar]
  10. Peck C. C., Barrett B. B. Nonlinear least-squares regression programs for microcomputers. J Pharmacokinet Biopharm. 1979 Oct;7(5):537–541. doi: 10.1007/BF01062394. [DOI] [PubMed] [Google Scholar]
  11. Raschack M. Relationship of antiarrhythmic to inotropic activity and antiarrhythmic qualities of the optical isomers of verapamil. Naunyn Schmiedebergs Arch Pharmacol. 1976 Sep;294(3):285–291. doi: 10.1007/BF00508397. [DOI] [PubMed] [Google Scholar]
  12. Reiter M. J., Shand D. G., Pritchett E. L. Comparison of intravenous and oral verapamil dosing. Clin Pharmacol Ther. 1982 Dec;32(6):711–720. doi: 10.1038/clpt.1982.227. [DOI] [PubMed] [Google Scholar]
  13. Saikawa T., Arita M. Effects of verapamil and its optical isomers on repetitive slow responses induced by electrical depolarization in canine ventricular myocardium. Jpn Heart J. 1980 Mar;21(2):247–255. doi: 10.1536/ihj.21.247. [DOI] [PubMed] [Google Scholar]
  14. Satoh K., Yanagisawa T., Taira N. Effects on atrioventricular conduction and blood flow of enantiomers of verapamil and of tetrodotoxin injected into the posterior and the anterior septal artery of the atrioventricular node preparation of the dog. Naunyn Schmiedebergs Arch Pharmacol. 1979 Aug;308(2):89–98. doi: 10.1007/BF00499049. [DOI] [PubMed] [Google Scholar]
  15. Schomerus M., Spiegelhalder B., Stieren B., Eichelbaum M. Physiological disposition of verapamil in man. Cardiovasc Res. 1976 Sep;10(5):605–612. doi: 10.1093/cvr/10.5.605. [DOI] [PubMed] [Google Scholar]
  16. Somogyi A., Albrecht M., Kliems G., Schäfer K., Eichelbaum M. Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. Br J Clin Pharmacol. 1981 Jul;12(1):51–60. doi: 10.1111/j.1365-2125.1981.tb01854.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Spiegelhalder B., Eichelbaum M. Determination of verapamil in human plasma by mass fragmentography using stable isotope-labelled verapamil as internal standard. Arzneimittelforschung. 1977;27(1):94–97. [PubMed] [Google Scholar]
  18. Wagner J. G. Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data. J Pharmacokinet Biopharm. 1976 Oct;4(5):443–467. doi: 10.1007/BF01062831. [DOI] [PubMed] [Google Scholar]
  19. Woodcock B. G., Rietbrock I., Vöhringer H. F., Rietbrock N. Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships. Clin Pharmacol Ther. 1981 Jan;29(1):27–34. doi: 10.1038/clpt.1981.5. [DOI] [PubMed] [Google Scholar]
  20. Woodcock B. G., Schulz W., Kober G., Rietbrock N. Direct determination of hepatic extraction of verapamil in cardiac patients. Clin Pharmacol Ther. 1981 Jul;30(1):52–56. doi: 10.1038/clpt.1981.126. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES